Bio-Rad Laboratories, Inc. (BIO) Balance Sheet
As of 2026-06-30 (10-Q), Bio-Rad Laboratories, Inc. (BIO) reported total assets of $10.3B, total liabilities of $3.1B and shareholders' equity of $7.2B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $517.0M. Long-term debt: $803.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BIOBio-Rad Laboratories, Inc.Follow BIO — free
—
Price chart with a free account
- Market cap
- 9.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.91 | 0.57 | 0.46 | 0.33 | 0.41 | 0.46 | 0.46 | 0.38 | 0.43 | 0.66 | 0.66 | 0.47 | 0.43 | 0.40 | 0.49 | 0.53 | 0.52 | |
| Short-term investments | 0.12 | 0.24 | 0.46 | 0.28 | 0.28 | 0.33 | 0.38 | 0.37 | 0.41 | 0.45 | 0.33 | 0.40 | 1.36 | 1.20 | 1.18 | 1.01 | 1.10 | |
| Receivables | — | 0.40 | 0.40 | 0.42 | 0.38 | 0.39 | 0.37 | 0.46 | 0.39 | 0.39 | 0.42 | 0.42 | 0.49 | 0.49 | 0.45 | 0.46 | 0.44 | |
| Inventory | 0.40 | 0.43 | 0.46 | 0.52 | 0.47 | 0.49 | 0.52 | 0.59 | 0.58 | 0.55 | 0.62 | 0.57 | 0.72 | 0.78 | 0.76 | 0.74 | 0.78 | |
| Current assets | 1.98 | 1.80 | 1.94 | 1.76 | 1.72 | 1.78 | 1.84 | 1.98 | 2.02 | 2.18 | 2.14 | 1.99 | 3.16 | 3.05 | 3.03 | 2.91 | 3.02 | |
| Total assets | 3.06 | 3.10 | 3.44 | 3.39 | 3.34 | 3.71 | 3.85 | 4.27 | 5.61 | 8.01 | 12.97 | 17.80 | 13.50 | 12.30 | 9.36 | 10.58 | 10.25 | |
| Current liabilities | 0.67 | 0.46 | 0.47 | 0.49 | 0.45 | 0.44 | 0.47 | 0.50 | 0.45 | 0.91 | 0.63 | 0.68 | 0.57 | 0.52 | 0.47 | 0.52 | 0.96 | |
| Long-term debt | 0.73 | 0.73 | 0.73 | 0.44 | 0.44 | 0.43 | 0.43 | 0.43 | 0.44 | 0.01 | 0.01 | 0.01 | 1.20 | 1.20 | 1.20 | 1.20 | 0.80 | |
| Short-term debt | 0.23 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Total liabilities | 1.52 | 1.35 | 1.43 | 1.20 | 1.16 | 1.22 | 1.27 | 1.34 | 1.59 | 2.25 | 3.09 | 4.11 | 3.89 | 3.56 | 2.79 | 3.12 | 3.08 | |
| Shareholders' equity | 1.54 | 1.74 | 2.02 | 2.19 | 2.18 | 2.49 | 2.58 | 2.93 | 4.02 | 5.76 | 9.89 | 13.69 | 9.62 | 8.74 | 6.57 | 7.45 | 7.17 |
USD billions · SEC XBRL
Bio-Rad Laboratories, Inc. — questions
- How much cash does Bio-Rad Laboratories, Inc. have?
- $517.0M in cash and cash equivalents as of 2026-06-30.
- How much debt does Bio-Rad Laboratories, Inc. have?
- $803.0M of long-term debt as of 2026-06-30.
- What are Bio-Rad Laboratories, Inc.'s total assets?
- $10.3B as of 2026-06-30.
- What is Bio-Rad Laboratories, Inc.'s shareholders' equity?
- $7.2B as of 2026-06-30.
Every figure on this page comes from Bio-Rad Laboratories, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.